Disc Medicine to Unveil APOLLO Phase 3 Trial Results for EPP Drug
Disc Medicine scheduled a webcast for Oct. 19 to present topline data from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria.
Watertown, Mass.-based Disc Medicine, Inc. (NASDAQ: IRON) announced it will host a corporate webcast Monday, October 19, 2026, at 8:00 a.m. ET to disclose topline results from the APOLLO Phase 3 clinical trial of bitopertin, an investigational therapy targeting erythropoietic protoporphyria (EPP).
Disc Medicine describes itself as a clinical-stage biopharmaceutical company focused on developing novel treatments for serious hematologic diseases. Bitopertin represents one of its lead pipeline candidates, and the APOLLO trial outcome is expected to be a pivotal data readout for the company's development program in EPP.
Read more Antheia Wins $80M Defense Dept Funding for Drug Manufacturing →
Erythropoietic protoporphyria is a rare inherited metabolic disorder that causes extreme sensitivity to light and can lead to severe pain and liver complications. Patients currently have limited approved treatment options, making late-stage trial results in this space closely watched by the rare-disease investment and medical communities.
The announcement of a specific webcast date and time suggests the company has data in hand and is preparing investors and stakeholders for a significant disclosure. Phase 3 topline results typically determine whether a drug sponsor will proceed toward a regulatory filing, making the October 19 event a potential inflection point for Disc Medicine's pipeline and stock.
Continue reading at GlobeNewswire - Industry News on Financial Services.
